IPP Bureau
Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
By IPP Bureau - December 30, 2025
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO’s DNA therapy for rare throat disease gets FDA review
By IPP Bureau - December 30, 2025
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies
By IPP Bureau - December 30, 2025
Harbour BioMed brings advanced antibody discovery platforms to the table
Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours
By IPP Bureau - December 30, 2025
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Next Gen Diagnostics to spin off infection prevention unit
By IPP Bureau - December 29, 2025
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
By IPP Bureau - December 29, 2025
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
By IPP Bureau - December 29, 2025
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure
By IPP Bureau - December 29, 2025
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
CPHI & PMEC India 2025 ignites pharma innovation and partnerships
By IPP Bureau - December 29, 2025
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
ENHERTU gains first-ever nod in China for metastatic breast cancer
By IPP Bureau - December 29, 2025
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe
By IPP Bureau - December 29, 2025
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Govt cancels registration of popular cosmetic product over misleading claims
By IPP Bureau - December 29, 2025
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
US House passes Bill reauthorizing FDA rare disease incentive program
By IPP Bureau - December 29, 2025
Akums and Sharda University ink MoU to bridge industry–academia gap
By IPP Bureau - December 29, 2025
The primary goal of the collaboration is joint research into trending and next-generation molecules
Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
By IPP Bureau - December 29, 2025
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
